Source: Eur Respir J, 55 (5) 1902026; 10.1183/13993003.02026-2019
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Oliver Distler, Shervin Assassi, Vincent Cottin, Maurizio Cutolo, Sonye K. Danoff, Christopher P. Denton, Jörg H.W. Distler, Anna-Maria Hoffmann-Vold, Sindhu R. Johnson, Ulf Müller Ladner, Vanessa Smith, Elizabeth R. Volkmann, Toby M. Maher. Predictors of progression in systemic sclerosis patients with interstitial lung disease. Eur Respir J, 55 (5) 1902026; 10.1183/13993003.02026-2019

Member's Comments

No comment yet.

Related content which might interest you: Disease course and outcome of progressive interstitial lung disease in systemic sclerosis Source: International Congress 2019 – Connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis: what’s new? Year: 2019 The natural course of systemic sclerosis patients with interstitial lung involvement Source: Eur Respir J 2005; 26: Suppl. 49, 336s Year: 2005 Interstitial lung disease with ANCA-associated vasculitis (AAV-ILD): Clinical features and survival compared to patients with ILD associated with systemic sclerosis and IPF Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key Year: 2020 Serum CC chemokine ligand-18 predicts lung disease worsening in systemic sclerosis Source: Eur Respir J 2011; 38: 1355-1360 Year: 2011 Predictors of mortality and risk prediction among patients with scleroderma related interstitial lung disease Source: International Congress 2015 – IPF: clinical aspects II Year: 2015 Pulmonary function tests as outcomes for systemic sclerosis interstitial lung disease Source: Eur Respir Rev, 27 (148) 170102; 10.1183/16000617.0102-2017 Year: 2018 Longitudinal functional evaluation of interstitial lung disease in systemic sclerosis Source: Virtual Congress 2020 – Diagnostic and prognostic markers for disease-associated interstitial lung disease and hypersensitivity pneumonitis Year: 2020 Clinical characteristics of interstitial lung fibrosis in progressive systemic sclerosis Source: Eur Respir J 2006; 28: Suppl. 50, 95s Year: 2006 Anti-a-enolase antibodies in systemic sclerosis identify a subset of patients with diffuse cutaneous sclerosis and interstitial lung disease Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders Year: 2008 Frequency and impact of interstitial lung disease on clinical state and mortality in systemic scleroderma Source: Annual Congress 2012 - Diffuse parenchymal lung disease III Year: 2012 Co-morbidities and cause of death in patients with rheumatoid arthritis associated interstitial lung disease Source: International Congress 2015 – Connective tissue disorders Year: 2015 Association of FVC/DLCO with pulmonary hypertension risk and interstitial disease in systemic sclerosis patients Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases Year: 2020 Early detection of subclinical interstitial lung disease in patients with rheumatoid arthritis and effect of methotrexate therapy Source: International Congress 2014 – ILDs 4 Year: 2014 Pulmonary physiology is poorly associated with radiological extent of disease in systemic sclerosis-associated interstitial lung disease Source: Eur Respir J, 53 (5) 1802182; 10.1183/13993003.02182-2018 Year: 2019 Potential causes of acute deterioration in patients with interstitial lung disease Source: Annual Congress 2010 - Different patterns of interstitial lung disease Year: 2010 Clinical manifestations of systemic sclerosis (SS) accompanied with pulmonary involvement Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 Addition of respiratory hospitalizations 24weeks prior to the ILD-GAP model to predict mortality in chronic interstitial lung disease Source: International Congress 2016 – Clinical aspects of ILD Year: 2016 Survival and prognostic factors in progressive systemic sclerosis with lung involvement Source: Annual Congress 2009 - Various backgrounds in diffuse parenchymal lung disease Year: 2009 IGFBP-2: a new pathway in systemic sclerosis associated interstitial lung disease Source: International Congress 2019 – Connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis: what’s new? Year: 2019 Pattern and impact of rheumatology referral in patients with ILD and autoimmune features Source: International Congress 2016 – Connective tissue disorders Year: 2016